Personal profile
Headline
PROFESSOR | Psychiatry, PROFESSOR | Neuroscience
Biography
Rachel Yehuda, PhD, Professor of Psychiatry and Neuroscience, is the Director of the Traumatic Stress Studies Division at the Mount Sinai School of Medicine which includes the PTSD clinical research program and the Neurochemistry and Neuroendocrinology laboratory at the James J. Peters Veterans Affairs Medical Center. Dr. Yehuda is a recognized leader in the field of traumatic stress studies. She has authored more than 250 published papers, chapters, and books in the field of traumatic stress and the neurobiology of PTSD. Her current interests include the study of risk and resilience factors, psychological and biological predictors of treatment response in PTSD, genetic and epigenetic studies of PTSD and the intergenerational transmission of trauma and PTSD. She has an active federally-funded clinical and research program that welcomes local and international students and clinicians. Dr. Yehuda's research on cortisol and brain function has revolutionized the understanding and treatment of PTSD worldwide and has been awarded the renowned Max Planck Institute for Psychiatry (Munich, Germany) 2004 Guest Professorship. The appointment signifies a special recognition of the outstanding research she has been performing in the field of neuroscience in the context of studies on causality of psychiatric disorders over the years. Dr. Yehuda received her PhD in Psychology and Neurochemistry and her MS in Biological Psychology from the University of Massachusetts at Amherst and completed her postdoctoral training in Biological Psychiatry in the Psychiatry Department at Yale Medical School. Multi-Disciplinary Training Area Neuroscience [NEU]
Fingerprint
Dive into the research topics where Rachel Yehuda is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Can Psychedelics Help Us Reimagine Prevention of Posttraumatic Stress Disorder?
Yehuda, R. & Charney, D. S., 2026, (Accepted/In press) In: Biological Psychiatry.Research output: Contribution to journal › Letter › peer-review
-
Author Correction: Modeling gene × environment interactions in PTSD using human neurons reveals diagnosis-specific glucocorticoid-induced gene expression(Nature Neuroscience, 10.1038/s41593-022-01161-y)
NYSCF Global Stem Cell Array® Team, Jan 2025, In: Nature Neuroscience. 28, 1, p. 214 1 p.Research output: Contribution to journal › Comment/debate
Open Access -
Combining Ketamine Infusions and Written Exposure Therapy for Chronic PTSD: An Open-Label Trial
Feder, A., Brown, O., Rutter, S. B., Cahn, L., Overbey, J. R., Seeley, S. H., Yu, A., Bonanno, P. A., Fremont, R. A., Delgado, A. A., Jha, M. K., Costi, S., Yehuda, R., Schiller, D., Pietrzak, R. H., Charney, D. S., Sloan, D. M. & Murrough, J. W., Jun 2025, In: Journal of Clinical Psychiatry. 86, 2, 24m15622.Research output: Contribution to journal › Article › peer-review
4 Scopus citations -
Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: A nonrandomized open-label clinical trial
McGowan, N. M., Rucker, J. J., Yehuda, R., Agrawal, M., Modlin, N. L., Simmons, H., Tofil-Kaluza, A., Das, S. & Goodwin, G. M., 2025, (Accepted/In press) In: Journal of Psychopharmacology. 02698811251362390.Research output: Contribution to journal › Article › peer-review
Open Access4 Scopus citations -
Investigational psilocybin treatment for post-traumatic stress disorder: a qualitative study of participant experience, trauma engagement, and differences from standard treatment
Modlin, N. L., Williamson, V., Goodwin, G. M., Malievskaia, E., Atli, M., Elek, Z., Gaillard, A., Koelpin, D., Cleare, A., Agrawal, M., Yehuda, R., Kirlic, N. & Rucker, J., Dec 2025, In: eClinicalMedicine. 90, 103692.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations
Press/Media
-
Active-duty US soldiers to receive psychedelic drugs for PTSD next year
30/04/26
2 items of Media coverage
Press/Media
-
Healing with Psychedelics: Veterans, PTSD, and the Science of Mind-Altering Drugs
30/04/26
1 item of Media coverage
Press/Media
-
Psychedelic Therapy for PTSD Set to Begin Trials with Active-Duty Soldiers
30/04/26
1 item of Media coverage
Press/Media
-
FDA Moves to Fast-Track Psychedelic Treatments for Severe Mental Health Disorders
27/04/26
1 item of Media coverage
Press/Media
-